629 related articles for article (PubMed ID: 18052111)
1. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
Baillie TA
Chem Res Toxicol; 2008 Jan; 21(1):129-37. PubMed ID: 18052111
[TBL] [Abstract][Full Text] [Related]
2. New horizons in drug metabolism, pharmacokinetics and drug discovery.
Palmer AM
Drug News Perspect; 2003; 16(1):57-62. PubMed ID: 12682673
[TBL] [Abstract][Full Text] [Related]
3. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
Srinivas NR
Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
[TBL] [Abstract][Full Text] [Related]
4. Applications of high-throughput ADME in drug discovery.
Kassel DB
Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in physicochemical and ADMET profiling in drug discovery.
Wang J; Skolnik S
Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
[TBL] [Abstract][Full Text] [Related]
6. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
7. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines.
Alavijeh MS; Palmer AM
IDrugs; 2004 Aug; 7(8):755-63. PubMed ID: 15334309
[TBL] [Abstract][Full Text] [Related]
8. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
[TBL] [Abstract][Full Text] [Related]
9. Lead optimization strategies as part of a drug metabolism environment.
Korfmacher WA
Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
[TBL] [Abstract][Full Text] [Related]
10. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
Lüpfert C; Reichel A
Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
[TBL] [Abstract][Full Text] [Related]
11. Discovery DMPK: changing paradigms in the eighties, nineties and noughties.
Summerfield S; Jeffrey P
Expert Opin Drug Discov; 2009 Mar; 4(3):207-18. PubMed ID: 23489121
[TBL] [Abstract][Full Text] [Related]
12. The future of discovery chemistry: quo vadis? Academic to industrial--the maturation of medicinal chemistry to chemical biology.
Hoffmann T; Bishop C
Drug Discov Today; 2010 Apr; 15(7-8):260-4. PubMed ID: 20149893
[TBL] [Abstract][Full Text] [Related]
13. The role of discovery DMPK scientists in industry: where do we go from here?
Moriwaki T
Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22531680
[No Abstract] [Full Text] [Related]
14. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.
Evans DC; Watt AP; Nicoll-Griffith DA; Baillie TA
Chem Res Toxicol; 2004 Jan; 17(1):3-16. PubMed ID: 14727914
[TBL] [Abstract][Full Text] [Related]
15. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?
Kalgutkar AS; Didiuk MT
Chem Biodivers; 2009 Nov; 6(11):2115-37. PubMed ID: 19937848
[TBL] [Abstract][Full Text] [Related]
16. Strategies for dealing with reactive intermediates in drug discovery and development.
Nassar AE; Lopez-Anaya A
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
[TBL] [Abstract][Full Text] [Related]
17. The development of drug metabolism research as expressed in the publications of ASPET: Part 2, 1959-1983.
Murphy PJ
Drug Metab Dispos; 2008 Jun; 36(6):981-5. PubMed ID: 18322071
[TBL] [Abstract][Full Text] [Related]
18. Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions.
Kumar S; Kassahun K; Tschirret-Guth RA; Mitra K; Baillie TA
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):43-52. PubMed ID: 18175266
[TBL] [Abstract][Full Text] [Related]
19. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics.
Roberts SA
Xenobiotica; 2001; 31(8-9):557-89. PubMed ID: 11569526
[TBL] [Abstract][Full Text] [Related]
20. Cellular models for ADMET predictions and evaluation of drug-drug interactions.
Riley RJ; Kenna JG
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):86-99. PubMed ID: 14982152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]